Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines.
The biotech's growth portfolio continues to add to its overall top line.
Biogen (NASDAQ:BIIB) executives pointed to a “very strong start” to 2026, highlighting growth in key products, progress ...
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by ...
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...
Investor's Business Daily on MSN
Biogen walloped Wall Street's first quarter views; here's what happened
Biogen obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep from its growth products.
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday.
AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.
Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Discover the strategic reasons ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of North Carolina's largest ...
Biogen employees work inside a lab used to produce cell cultures in 2014 at the firm’s Research Triangle Park facilities. N&O file photo Biogen commits $2 billion to expand RTP campuses in Wake and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results